Exosome Diagnostics Announces Additions to Management Team
NEW YORK, Sept. 3 /PRNewswire/ — Exosome Diagnostics, Inc. today announced additions to its management team as the company moves forward with development of its blood-based diagnostics that can identify cancer-specific genetic mutations.
Wayne D. Comper, Ph.D., D.Sc., has joined Exosome Diagnostics as the chief scientific officer. Dr. Comper has extensive experience both as a biotechnology executive and as a biomedical research scientist. Prior to joining Exosome, he was chief science officer of AusAm Biotechnologies, Inc., a company developing diagnostics and therapeutics to identify and treat kidney, cardiovascular and infectious diseases. Dr. Comper has also published over 160 articles in peer-reviewed international journals. Dr. Comper received both his Ph.D. and D.Sc. from Monash University, Clayton, Victoria, Australia.
Tom Tsakeris has been appointed director of regulatory affairs. Mr. Tsakeris’ expertise includes extensive experience with the Food and Drug Administration (FDA) and as an advisor to companies on the regulatory approval process. Prior to joining Exosome, Mr. Tsakeris was president of Devices and Diagnostics Consulting Group, Inc. His prior positions also include director of the Division of Clinical Laboratory Devices, Office of Device Evaluation, Center for Devices and Radiological Health and several other management roles at FDA. During his tenure at FDA, he played a key role in developing the implementation strategy for the Clinical Laboratory Improvement Act (CLIA) of 1988.
“With our exosome technology, we are able to overcome a fundamental issue of how to capture diagnostic quantities of genetic mutations in blood,” said James McCullough, chairman & chief executive officer. “These mutations contain enormous amounts of information specific to different types of cancers that can be used for diagnosis and disease monitoring. These important management additions will now enable us to expand clinical development of our first blood-based genomic test for neuroblastoma, complete a partnership with a CLIA-approved clinical laboratory and launch of our first clinical diagnostic in 2009.”
About Exosome Diagnostics
Exosome Diagnostics is a developer of proprietary genetics-based diagnostic tests with applications in oncology and endocrinology. Exosome’s core technology is based on the discovery that circulating nanovesicles called exosomes contain unique genetic markers and that they can be reliably harvested and used as a diagnostic tool for cancers and metabolic diseases. Exosome Diagnostics’ lead program is a blood-based diagnostic test for the management of neuroblastoma patients. For more information, visit http://www.exosomedx.com/.
Media Contacts: Robert Flamm, Ph.D., or David Schull Russo Partners (212) 845-4226 firstname.lastname@example.org email@example.com
Exosome Diagnostics, Inc.
CONTACT: Robert Flamm, Ph.D., firstname.lastname@example.org, orDavid Schull, email@example.com, both of Russo Partners,+1-212-845-4226
Web site: http://www.exosomedx.com/